In vivo response to methotrexate forecasts outcome of acute lymphoblastic leukemia and has a distinct gene expression profile.

In vivo response to methotrexate forecasts outcome of acute lymphoblastic leukemia and has a distinct gene expression profile.

Childhood acute lymphoblastic leukemia (ALL) is the most common cancer in children, and can now be cured in approximately 80% of patients. Nevertheless, drug resistance is the major cause of treatment failure in children with ALL. The drug methotrexate (MTX), which is widely used to treat many human...

Full description

Bibliographic Details
Main Authors: Michael J Sorich, Nicolas Pottier, Deqing Pei, Wenjian Yang, Leo Kager, Gabriele Stocco, Cheng Cheng, John C Panetta, Ching-Hon Pui, Mary V Relling, Meyling H Cheok, William E Evans
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2008-04-01
Series:PLoS Medicine
Online Access:http://europepmc.org/articles/PMC2292747?pdf=render

Internet

http://europepmc.org/articles/PMC2292747?pdf=render

Similar Items